Early investigational drugs targeting PPAR-α for the treatment of metabolic disease

Expert Opinion on Investigational Drugs

Volumn 24, Issue 5, 2015, Pages 611-621

  Liu, Zhong Min ^a   Hu, Miao ^b   Chan, Paul ^c   Tomlinson, Brian ^b  

^a TONGJI UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Atherogenic dyslipidemia; Fenofibrate; GFT 505; K 877; PPAR agonists

Indexed keywords

2 [2,6 DIMETHYL 4 [3 [4 (METHYLTHIO)PHENYL] 3 OXO 1 PROPENYL]PHENOXY] 2 METHYLPROPIONIC ACID; 2 [3 [[(BENZOXAZOL 2 YL)[3 (4 METHOXYPHENOXY)PROPYL]AMINO]METHYL]PHENOXY]BUTANOIC ACID; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; 2-(2,6-DIMETHYL-4-(3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPENYL)PHENOXYL)-2-METHYLPROPANOIC ACID; BENZOXAZOLE DERIVATIVE; BUTYRIC ACID DERIVATIVE; CHALCONE DERIVATIVE; K-877 COMPOUND; NEW DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROPIONIC ACID DERIVATIVE;

ARTICLE; ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; UNSPECIFIED SIDE EFFECT; AGONISTS; ANIMAL; DRUG DESIGN; METABOLIC DISEASES; PATHOPHYSIOLOGY;

ANIMALS; BENZOXAZOLES; BUTYRATES; CHALCONES; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; METABOLIC DISEASES; PPAR ALPHA; PPAR GAMMA; PROPIONATES;

EID: 84927602643     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1006359     Document Type: Article

References (82)

1. Anand SS, Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet 2011;377:529-32
2. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61
3. Tilg H, Moschen AR. Evolving therapies for non-alcoholic steatohepatitis. Expert Opin Drug Discov 2014;9:687-96
4. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-45
5. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217:3-46
6. Carey VJ, Bishop L, Laranjo N, et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of lowdensity lipoprotein cholesterol control. Am J Cardiol 2010;106:757-63
7. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102:1K-34K
8. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000
9. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014;2:655-66
10. Rabar S, Harker M, O'Flynn N, et al. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014;349:g4356
11. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008;5:542-53
12. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-50
13. Issemann I, Prince RA, Tugwood JD, et al. The peroxisome proliferatoractivated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol 1993;11:37-47
14. Auwerx J, Schoonjans K, Fruchart JC, et al. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 1996;124(Suppl):S29-37
15. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25
16. Fruchart JC. Peroxisome proliferatoractivated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009;205:1-8
17. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997;272:18779-89
18. Fajas L, Fruchart JC, Auwerx J. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 1998;438:55-60
19. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
20. Tolman KG. The safety of thiazolidinediones. Expert Opin Drug Saf 2011;10:419-28
21. Riserus U, Sprecher D, Johnson T, et al. Activation of peroxisome proliferatoractivated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008;57:332-9
22. Fruchart JC. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferatoractivated receptor alpha-agonists. Cardiovasc Diabetol 2013;12:82
23. Fruchart JC. Novel peroxisome proliferator activated receptor-alpha agonists. Am J Cardiol 2007;100:n41-6
24. Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006;58:726-41
25. Gervois P, Fruchart JC, Staels B. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007;3:145-56
26. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45
27. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group. N Engl J Med 1999;341:410-18
28. Manttari M, Huttunen JK, Koskinen P, et al. Lipoproteins and coronary heart disease in the Helsinki Heart Study. Eur Heart J 1990;11(Suppl H):26-31
29. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102:21-7
30. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-60
31. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-7
32. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
33. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-8
34. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
35. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84
36. Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007;154:943-53
37. Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780-8
38. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97
39. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44
40. Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:280-90
41. Impellizzeri D, Esposito E, Attley J, et al. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). Pharmacol Res 2014;81:91-102
42. Noonan JE, Jenkins AJ, Ma JX, et al. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes 2013;62:3968-75
43. Herrmann M, Whiting MJ, Veillard AS, et al. Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study. Clin Chem Lab Med 2012;50:2213-19
44. Liu WY, Huang S, Shi KQ, et al. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. Expert Opin Ther Targets 2014;18:1305-13
45. Christodoulides C, Dyson P, Sprecher D, et al. Circulating fibroblast growth factor 21 is induced by peroxisome proliferatoractivated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 2009;94:3594-601
46. Ong KL, Rye KA, O'Connell R, et al. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinolbinding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab 2012;97:4701-8
47. Bays HE, Jones PH, Mohiuddin SM, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol 2008;2:426-35
48. Xu HE, Lambert MH, Montana VG, et al. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 2001;98:13919-24
49. Thomas J, Bramlett KS, Montrose C, et al. A chemical switch regulates fibrate specificity for peroxisome proliferatoractivated receptor alpha (PPARalpha) versus liver X receptor. J Biol Chem 2003;278:2403-10
50. Fievet C, Fruchart JC, Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006;6:606-14
51. Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/ gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374:126-35
52. Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 2014;311:1515-25
53. Agrawal R. The first approved agent in the Glitazar's Class: saroglitazar. Curr Drug Targets 2014;15:151-5
54. Jani RH, Pai V, Jha P, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther 2014;16:63-71
55. Pai V, Paneerselvam A, Mukhopadhyay S, et al. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V). J Diabetes Sci Technol 2014;8:132-41
56. Yamazaki Y, Abe K, Toma T, et al. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. Bioorg Med Chem Lett 2007;17:4689-93
57. Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and nonalcoholic fatty liver disease. Expert Opin Pharmacother 2014;15:493-503
58. Iwata H, Murakami K, Ricchiuto P, et al. Abstract 16180: K-877, a novel PPAR-alpha selective agonist, suppresses macrophage activation and arterial lesion formation. Circulation 2013;128:A16180
59. Takizawa T, Inokuchi Y, Goto S, et al. Abstract 12867: The mechanism of K- 877, a highly potent and selective pparalpha modulator, on regulation of synthesis, secretion and metabolism of triglycerides and cholesterol. Circulation 2013;128:A12867
60. Masuda D, Kobayashi T, Okada T, et al. A novel potent and selective PPARalpha agonist, K-877, ameriolates both fasting and postprandial hypertriglyceridemia. Atherosclerosis 2014;235:E169-E70
61. Ishibashi S. Benefical effects of K-877, a potent and highly selective PPARalpha agonist, on plasma lipoprotein profile in patients with atherogenic dyslipidemia [abstract 525]. In Proceedings of 80th EAS Congress; Milan, Italy; 2012
62. Yokote K, Ishibashi S, Yamashita S, et al. Abstract 17336: Marked increase of plasma fibroblast growth factor 21 in dyslipidemic patients treated with K-877, a novel highly potent and specific peroxisome proliferator-activated receptor alpha agonist. Circulation 2013;128:A17336
63. Ishibashi S. Suppression of postprandial triglyceride, Remnant-like Particles- Cholesterol (RLP-C) and ApoB48 surge by K-877, a potent and highly selective PPARa agonist. Abstract 618 In Proceedings of 80th EAS Congress; Milan, Italy; 2012
64. Ishibashi S, Yamashita S, Arai H, et al. Abstract 10718: Efficacy and Safety of K-877, a Potent and Selective PPAR-a Agonist, in Japanese Patients With Dyslipidemia. Circulation 2013;128:A10718
65. Yamashita S, Ishibashi S, Arai H, et al. Abstract 15652: Comparison of the novel peroxisome proliferator-activated receptor alpha agonist K-877 and fenofibrate on high-density lipoprotein subclass distribution determined by highperformance liquid chromatography in patients with dyslipidemia. Circulation 2013;128:A15652
66. Arai H, Ishibashi S, Yamashita S, et al. Abstract 13118: The novel highly potent and specific peroxisome proliferatoractivated receptor alpha agonist K-877 improved liver enzymes and lipid profile without adversely affecting renal functions; integrated analysis of phase 2 and phase 2/3 double blind clinical trials. Circulation 2013;128:A13118
67. Cariou B, Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Investig Drugs 2014;23:1441-8
68. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferatoractivated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013;36:2923-30
69. Staels B, Rubenstrunk A, Noel B, et al. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis. Hepatology 2013;58:1941-52
70. Hanf R, Millatt LJ, Cariou B, et al. The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gammaassociated adverse cardiac effects. Diab Vasc Dis Res 2014;11:440-7
71. Cariou B, Zair Y, Staels B, et al. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011;34:2008-14
72. Merck Announces that IMPROVE-IT Achieved Primary Endpoint. Data to be Presented at American Heart Association Scientific Sessions Today. 17 November 2014 Available from: http://www. mercknewsroom.com/news-release/ prescription-medicine-news/merckannounces- improve-it-achieved-primaryendpoint- data-be
73. Blazing MA, Giugliano RP, Cannon CP, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014;168:205-12.e1
74. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014;11:563-75
75. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
76. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12
77. Hu M, Tomlinson B. Niacin for reduction of cardiovascular risk. N Engl J Med 2014;371:1941-2
78. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
79. Bajaj M, Suraamornkul S, Hardies LJ, et al. Effects of peroxisome proliferatoractivated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007;50:1723-31
80. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010;95:2727-35
81. Kim JI, Tsujino T, Fujioka Y, et al. Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res 2003;26:307-13
82. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50